Keyword: Beovu

Regeneron touts Eylea's multiple indications, established user experience and a newly launched prefilled injector as Novartis' rival Beovu enters.

Regeneron is sharpening Eylea's edge with prefilled syringes, a launch in diabetic retinopathy and tests of a higher dose to increase its durability.

It's still very early in Novartis' launch of wet age-related macular degeneration drug Beovu, but doctors are excited, one exec said.

Novartis' Beovu will be going up against entrenched rivals with a couple blemishes in its label, analysts wrote.

Novartis has its next big drug approval. The FDA on Tuesday approved wet AMD drug Beovu, which will go up against Regeneron and Roche meds.